Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00035464
Other study ID # 2000037
Secondary ID
Status Completed
Phase Phase 3
First received May 3, 2002
Last updated September 30, 2011
Start date December 2000
Est. completion date January 2004

Study information

Verified date September 2011
Source Forest Laboratories
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Atrial fibrillation (an abnormal rhythm in the upper chamber of the heart) is a common supraventricular arrhythmia (a type of abnormal heart rhythm) for which antiarrhythmic therapy is often prescribed. The primary goals of therapy are to maintain sinus rhythm (normal heart rhythm) and to reduce the occurrence of episodes of atrial fibrillation. Azimilide may have an effect on increasing the time to first recurrence of symptomatic atrial fibrillation or atrial flutter and symptomatic paroxysmal supraventricular tachycardia (other types of abnormal heart rhythms).

This double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of azimilide compared with placebo in prolonging the time to the first symptomatic arrhythmia recurrence in patients with a history of atrial fibrillation and congestive heart failure and/or ischemic heart disease) and those without these conditions. Once this phase of the study is completed, a second phase with a different study design will be conducted. The second phase is an open-label, follow-up phase. The follow-up phase of the study is designed to evaluate the long-term efficacy and safety of a daily oral dose of azimilide in patients who complete the double-blind, placebo-controlled phase of this study.


Recruitment information / eligibility

Status Completed
Enrollment 431
Est. completion date January 2004
Est. primary completion date January 2004
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion criteria:

- History of symptomatic atrial fibrillation that significantly disrupts the patient's customary daily living activities

- History of congestive heart failure and/or ischemic heart disease

- Sinus rhythm (normal heart rhythm) upon entry to the 30 day screening period for the study

- At least one episode of symptomatic atrial fibrillation during the screening period, with a spontaneous return to sinus rhythm.

- Sinus rhythm immediately prior to dosing

Exclusion criteria:

- Previously unsuccessful cardioversions within 60 days of screening period

- Failed to respond to any Class III antiarrhythmic drugs

- Qualifying arrhythmia due to acute reversible illness, acute myocardial infarction, and/or cardiac or thoracic surgery within one month prior to randomization

- Previously in an azimilide study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Azimilide Dihydrochloride
125 mg azimilide tablets, twice a day for 6 months
Placebo
placebo tablets, twice a day for 6 months

Locations

Country Name City State
Canada Heart Health Institute Calgary Alberta
Canada Heart Health Research Center Calgary Alberta
Canada University of Calgary Calgary Alberta
Canada Hamilton Health Science Corp. Hamilton Ontario
Canada Cardiac Investigation Unit London Ontario
Canada Chum Hotel Dieu Montreal Quebec
Canada Hospital Sacre-Soeur de Montreal Montreal Quebec
Canada Montreal Heart Institute Montreal Quebec
Canada Recharche Cardiologie Montreal Quebec
Canada Niagara Health System Greater Niagara General Hospital Niagara Falls Ontario
Canada University of Ottawa Heart Institute Ottawa Ontario
Canada Quebec Heart Institute Sainte-Foy Quebec
Canada Neureka Research Corporation Sudbury Ontario
Canada St. Michael's Hospital Toronto Ontario
Canada Cardiology Research St. Paul's Hospital Vancouver British Columbia
United States VA Medical Center Therapeutic Section :Minneapolis Minnesota
United States Heart Care Group PC Allentown Pennsylvania
United States Aurora Denver Cardiology Aurora Colorado
United States Tri-State Medical Group Cardiology Beaver Pennsylvania
United States Beloit Clinic, SC Beloit Wisconsin
United States Cardiovascular Assoc. PC Birmingham Alabama
United States Boston Medical Center Boston Massachusetts
United States Cardiovascular Associates of Penisula Burlingame California
United States Capitol Interventional Cardiology Carmichael California
United States Charleston Cardiology Charleston South Carolina
United States MedSource, Inc Chesapeake Virginia
United States Mount Sinal Hospital Medical Center Chicago Illinois
United States Lindner Clinical Trial Ctr. Cincinnati Ohio
United States University Hospitals of Cleveland Cleveland Ohio
United States MidWest Cardiology Research Foundation Columbus Ohio
United States UT Southwestern Medical Center Dallas Texas
United States Cardiology Consultants Daytona Beach Florida
United States VA Medical Center Decatur Georgia
United States Western Cardiology Assoc. Denver Colorado
United States Regional Heart Center Duluth Minnesota
United States Duke Medical Center Durham North Carolina
United States Elgin Cardiology Associates Elgin Illinois
United States C/O Research Office Attn: Cardiovascular Research Dept. Fort Lauderdale Florida
United States VA Central California Health Care System Fresno California
United States Valley Research Fresno California
United States SW Florida Heart Group/Health Park Medical Center Ft. Myers Florida
United States Heart Center Medical Group Ft. Wayne Indiana
United States Altru Health System Research Center Grand Forks North Dakota
United States Internal Medical Associates Grand Island Nebraska
United States Grass Valley Cardiology Grass Valley California
United States Hartford Hospital Hartford Connecticut
United States Milton S. Hershey Medical Center Hershey Pennsylvania
United States Fairview Range Regional Health Services Hibbing Minnesota
United States Hillsboro Cardiology Hillsboro Oregon
United States Cardiovascular Institute of the South Houma Louisiana
United States Methodist Hospital Houston Texas
United States The Care Group Indianapolis Indiana
United States Jacksonville Center for Clinical Research Jacksonville Florida
United States Dean/Riverview Clinic Janesville Wisconsin
United States The Pavillion Jenkintown Pennsylvania
United States San Diego Cardiovascular Associates La Jolla California
United States Richard Gilmore, MD 501 S Ryan Street Lake Charles Louisiana
United States Watson Clinic, LLP Lakeland Florida
United States Thoracic & Cardiovascular Healthcare Foundation Lansing Michigan
United States University of Arkansas Medical Center Little Rock Arkansas
United States Cardiology Section, West Los Angeles VA Hospital Los Angeles California
United States Good Samaritan Hospital Los Angeles California
United States LAC+USC Medical Center Los Angeles California
United States Louisville Cardiology Medical Group, P.S.C Louisville Kentucky
United States University of Louisville-Cardiology Louisville Kentucky
United States University of Wisconsin Madison Madison Wisconsin
United States Marshfield Clinic Marshfield Wisconsin
United States Stern Cardiovascular Center Research Department Memphis Tennessee
United States Merced Heart Associates Merced California
United States Khalid Hassan Sheikh 80 Fontenberry Road Merritt Island Florida
United States St. Patrick Hosp/Western Mt. Clinic Cardiology Missoula Montana
United States The Heart Group, PC Mobile Alabama
United States Sutter Gould Medical Foundation Modesto California
United States Cardiovascular of the South Morgan City Louisiana
United States Cardiovascular Institute of the South New Iberia Louisiana
United States Tulane University New Orleans Louisiana
United States Riverside Regional Medical Center Newport News Virginia
United States Illinois Heart & Lung Research Center, SC Normal Illinois
United States Oklahoma Foundation for Cardiovascular Research Oklahoma City Oklahoma
United States Florida Cardiology Orlando Florida
United States Cardiology Research Assiocates Ormond Beach Florida
United States The Center for Advanced Cardiology Park Ridge Illinois
United States Nisus Research Petoskey Michigan
United States UPHS/Presbyterian Medical Center Philadelphia Pennsylvania
United States Cardiovascular and Critical Care Associates, P.C. Pittsburgh Pennsylvania
United States Maine Medical Center Portland Maine
United States Oregon Health Sciences University Portland Oregon
United States ARI Clinical Trials Redondo Beach California
United States William Olney, MD 21 Whitehall Rd, Suite 200 Rochester New Hampshire
United States Regional Cardiology Assoc. Sacramento California
United States Sacramento Heart and Vascular Medical Associates Sacramento California
United States Heart and Vascular Inst. of Texas, PA San Antonio Texas
United States Cardiology Associates San Diego California
United States Daniel Gottlieb, MD 16259 Sylvester Road SW, Suite 401 Seattle Washington
United States Medical Research Institute Slidell Louisiana
United States Cardiovascular Institute of the South Thibodaux Louisiana
United States Riverside Osteopathic Hospital Trenton Michigan
United States Southern Arizona VA Health Care System, Section of Cardiology (1-111C) Tucson Arizona
United States University Medical Center Tucson Arizona
United States The George Washington University MFA Washington District of Columbia
United States Professional Research Network of Kansas Wichita Kansas
United States Cardiology & Int. Medicine Williamsville New York
United States University of Massachusett Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Forest Laboratories

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary To prolong the tachycardia-free period in patients 6 months No
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A